» Articles » PMID: 26600474

Intensity of Medical Interventions Between Diagnosis and Death in Patients with Advanced Lung and Colorectal Cancer: A CanCORS Analysis

Overview
Journal J Palliat Med
Specialty Critical Care
Date 2015 Nov 25
PMID 26600474
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Medical interventions are an important component of the illness experience in advanced cancer.

Objective: To describe the use of medical interventions between diagnosis and death in decedents with metastatic lung and colorectal cancer.

Design: Retrospective analysis of a prospective cohort study.

Setting/subjects: We studied 1,840 decedents from the Cancer Care Outcomes Research and Surveillance (CanCORS) study. Subjects had been diagnosed with stage IV lung or colorectal cancer between 2003 and 2005.

Measurements: Hospitalizations, surgeries, radiation therapy treatments, chemotherapy treatments, and end-of-life care, reported by tertile of overall survival time.

Results: Median survival in the bottom, middle, and top tertiles of survival was 1.2, 5.3, and 15.3 months for lung cancer, and 3.0, 18.0, and 44.4 months for colorectal cancer. Hospitalizations, chemotherapy receipt, and hospice enrollment increased with increasing survival. The median duration of chemotherapy in the top survival tertile was 149 days for lung cancer and 498 days for colorectal cancer. A minority of decedents used any hospice services, and the median duration of hospice enrollment exceeded 30 days only for enrollees in the top survival tertile (lung cancer, 35 days; colorectal cancer, 66 days).

Conclusions: For patients with metastatic lung and colorectal cancer, longer survival is associated with increased intensity of medical care, characterized by greater use of chemotherapy and acute hospital care. Hospice utilization was uniformly low, and most hospice enrollees were referred to hospice in the last 30 days of life.

Citing Articles

Development of a prognostic model to predict 90-day mortality in hospitalised cancer patients (PROMISE tool): a prospective observational study.

Mirallas O, Martin-Cullell B, Navarro V, Vega K, Recuero-Borau J, Gomez-Puerto D Lancet Reg Health Eur. 2024; 46:101063.

PMID: 39529819 PMC: 11551497. DOI: 10.1016/j.lanepe.2024.101063.


Predictors of high-intensity care at the end of life among older adults with solid tumors: A population-based study.

Baird C, Wulff-Burchfield E, Egan P, Hugar L, Vyas A, Trikalinos N J Geriatr Oncol. 2024; 15(5):101774.

PMID: 38676975 PMC: 11162260. DOI: 10.1016/j.jgo.2024.101774.


Duration of palliative care before death in international routine practice: a systematic review and meta-analysis.

Jordan R, Allsop M, ElMokhallalati Y, Jackson C, Edwards H, Chapman E BMC Med. 2020; 18(1):368.

PMID: 33239021 PMC: 7690105. DOI: 10.1186/s12916-020-01829-x.


Intensity of End-of-Life Care in a Cohort of Commercially Insured Women With Metastatic Breast Cancer in the United States.

Ferrario A, Xu X, Zhang F, Ross-Degnan D, Wharam J, Wagner A JCO Oncol Pract. 2020; 17(2):e194-e203.

PMID: 33170746 PMC: 8258118. DOI: 10.1200/OP.20.00089.


Unrealistic parental expectations for cure in poor-prognosis childhood cancer.

Mack J, Cronin A, Uno H, Shusterman S, Twist C, Bagatell R Cancer. 2019; 126(2):416-424.

PMID: 31584705 PMC: 7523918. DOI: 10.1002/cncr.32553.


References
1.
Emanuel E, Young-Xu Y, Levinsky N, Gazelle G, Saynina O, Ash A . Chemotherapy use among Medicare beneficiaries at the end of life. Ann Intern Med. 2003; 138(8):639-43. DOI: 10.7326/0003-4819-138-8-200304150-00011. View

2.
Hu C, Bailey C, You Y, Skibber J, Rodriguez-Bigas M, Feig B . Time trend analysis of primary tumor resection for stage IV colorectal cancer: less surgery, improved survival. JAMA Surg. 2015; 150(3):245-51. DOI: 10.1001/jamasurg.2014.2253. View

3.
Murthy V, Krumholz H, Gross C . Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA. 2004; 291(22):2720-6. DOI: 10.1001/jama.291.22.2720. View

4.
Ayanian J, Chrischilles E, Fletcher R, Fouad M, Harrington D, Kahn K . Understanding cancer treatment and outcomes: the Cancer Care Outcomes Research and Surveillance Consortium. J Clin Oncol. 2004; 22(15):2992-6. DOI: 10.1200/JCO.2004.06.020. View

5.
Kiely B, Soon Y, Tattersall M, Stockler M . How long have I got? Estimating typical, best-case, and worst-case scenarios for patients starting first-line chemotherapy for metastatic breast cancer: a systematic review of recent randomized trials. J Clin Oncol. 2010; 29(4):456-63. DOI: 10.1200/JCO.2010.30.2174. View